Expertise in
13
conditions

Dr. Emily C. Daugherty

Radiation Oncology
University Of Cincinnati Physicians Company LLC
3188 Bellevue Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
13
conditions
University Of Cincinnati Physicians Company LLC
3188 Bellevue Ave, 
Cincinnati, OH 

Overview

Emily Daugherty is a Radiation Oncologist practicing medicine in Cincinnati, Ohio.

Dr. Daugherty is highly rated in 13 conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 9 clinical trials. Dr. Daugherty is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in OH

Hospital Affiliations

West Chester Hospital
University Of Cincinnati Medical Center, LLC

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
3188 Bellevue Ave, Cincinnati, OH 45219

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
Enrollment Status: Recruiting
Publish Date: April 17, 2026
Intervention Type: Other, Device
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Suspended
Publish Date: September 04, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Other, Drug, Biological, Radiation
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol
Enrollment Status: Terminated
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Study Phase: Phase 2
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: September 26, 2023
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide, Paclitaxel, Pemetrexed
Study Phase: Phase 2
View 8 Less Clinical Trials

15 Total Publications

FAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases.
FAST-02: Results from the second in-human prospective evaluation of single-fraction proton FLASH for symptomatic thoracic bone metastases.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: March 11, 2026
Similar Doctors
Expertise in
6
conditions
Dr. Vinita Takiar
Radiation Oncology
Expertise in
6
conditions
Dr. Vinita Takiar
Radiation Oncology
Referral may be required

Barrett Building-Breast Imaging

3151 Bellevue Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-584-3494
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Vinita Takiar is a Radiation Oncologist practicing medicine in Cincinnati, Ohio. Dr. Takiar is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy. Dr. Takiar is currently accepting new patients.

Expertise in
30
conditions
Dr. John C. Breneman
Radiation Oncology
Expertise in
30
conditions
Dr. John C. Breneman
Radiation Oncology
Referral may be required

University Of Cincinnati Medical Center

3199 Highland Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-584-4775
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Breneman is a Radiation Oncologist practicing medicine in Cincinnati, Ohio. Dr. Breneman is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Meningioma, Brain Tumor, Optic Glioma, and Radiation Induced Meningioma. Dr. Breneman is currently accepting new patients.

Expertise in
17
conditions
Dr. Jordan R. Kharofa
Radiation Oncology
Expertise in
17
conditions
Dr. Jordan R. Kharofa
Radiation Oncology
Referral may be required

West Chester Hospital Radiotherapy Center

7710 Discovery Dr, 
West Chester, OH 
 (18.0 miles away)
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jordan Kharofa is a Radiation Oncologist practicing medicine in West Chester, Ohio. He has been practicing medicine for over 17 years. Dr. Kharofa is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Anal Cancer, Pancreatic Cancer, Vaginal Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Kharofa is currently accepting new patients.

Frequently Asked Questions about Dr. Emily C. Daugherty

How do I make an appointment with Dr. Emily C. Daugherty?

You can book an appointment with Dr. Emily C. Daugherty by calling their office at 513-584-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Emily C. Daugherty a top-rated expert for Pleuropulmonary Blastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Emily C. Daugherty is classified as an Distinguished expert for Pleuropulmonary Blastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Emily C. Daugherty specialize in?

While Dr. Emily C. Daugherty is a Radiation Oncology, they have specific expertise in Pleuropulmonary Blastoma, Lung Cancer, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Emily C. Daugherty participate in research or clinical trials?

Yes. Dr. Emily C. Daugherty has published 15 articles and abstracts on conditions like Pleuropulmonary Blastoma. You can view a list of Dr. Emily C. Daugherty's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Emily C. Daugherty accept my insurance?

Dr. Emily C. Daugherty accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 513-584-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daugherty's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile